OR51E2 and cancer: In summary, we investigate the molecular interaction of the antagonist/agonist combination (R)- α-/ (S)- α-/ β-ionone on the ectopically expressed olfactory receptor PSGR, which is a potential anti-cancer drug target for prostate cancer, and especially the difficult to treat melanoma cancer.